- Home
- ONCY vs IMA Comparison
ONCY vs IMA Comparison
Compare ONCY & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCY | IMA |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 66.3M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ONCY | IMA |
|---|---|---|
| Price | $0.50 | $4.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.16 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.2M | 10.7K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $3.90 |
| 52 Week High | $1.32 | $9.10 |
Technical Indicators
Market Signals| Indicator | ONCY | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 30.51 |
| Support Level | $0.44 | $3.92 |
| Resistance Level | $0.89 | $6.13 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 35.23 | 21.95 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.